Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

This publication has 13 references indexed in Scilit:

• A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia
  Blood, 2002
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
  Blood, 2001
• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
  New England Journal of Medicine, 2001
• Identification of the Major Positional Isomer of Pegylated Interferon Alpha-2b
  Biochemistry, 2000
• Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
  Journal of Clinical Oncology, 2000
• The use of the New york heart association's classification of cardiovascular disease as part of the patient's complete problem list
  Clinical Cardiology, 1999
• Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine
  Journal of Clinical Oncology, 1999
• Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 1997
• Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia
  The American Journal of Medicine, 1990